What is Alcami?
Headquartered in North Carolina, Alcami operates as a comprehensive partner for pharmaceutical and biotech enterprises, boasting over four decades of industry expertise. The organization manages an expansive operational footprint of 675,000 square feet across the United States, providing a robust infrastructure for analytical development and manufacturing. Their service portfolio is highly diversified, encompassing sterile and oral solid manufacturing, packaging, microbiology, and cGMP biostorage. By offering customizable solutions, Alcami enables clients to navigate the rigorous regulatory landscape while accelerating time-to-market for essential therapeutic products. Their commitment to environmental monitoring and pharmaceutical support services further cements their status as a vital link in the global life sciences ecosystem.
How much funding has Alcami raised?
Alcami has raised a total of $31M across 1 funding round:
Unspecified
$31M
Unspecified (2021): $31M, investors not publicly disclosed
Key Investors in Alcami
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Alcami?
With this major enterprise-level funding, Alcami is well-positioned to enhance its technical capabilities and expand its manufacturing capacity to meet the growing demand for specialized pharmaceutical services. The strategic allocation of this capital will likely focus on upgrading cGMP facilities and integrating advanced analytical technologies to maintain a competitive edge in the CDMO sector. As the industry shifts toward more complex biologic and small-molecule therapies, Alcami's focus on scalable, end-to-end solutions will be instrumental in driving long-term growth. Future initiatives will likely prioritize operational efficiency and the expansion of their sterile manufacturing footprint, ensuring the company remains a preferred partner for global biotech firms seeking reliable, high-quality development and production support.
See full Alcami company page
